Adverse Drug Reactions and Quality of Life in Schizophrenia Patients with Chronic Viral Hepatitis

Schizophrenia patients frequently develop somatic co-morbidity, including chronic viral hepatitis. The study of the quality of life in schizophrenia patients with concomitant viral hepatitis in the context of hospital pharmacotherapy, therefore, becomes an important task. We examined 60 schizophrenia patients with chronic viral hepatitis. Diagnosis was based on clinical, psychopathological, psychometric, clinical and laboratory methods, followed by statistical data processing. The features relating to the socio-demographic status, adaptation to work, and the prevalence of co-morbid alcohol and drug abuse were identified in this group. Also, correlations between the severity of psychotic disorders and the development of adverse drug reactions were revealed in schizophrenia patients with concomitant viral hepatitis. Schizophrenia patients with concomitant chronic viral hepatitis are a very difficult-to-treat patient group. Therefore, it becomes essential to create and implement individual treatment and rehabilitation programs in clinical practice, to improve the quality of life and prevention of druginduced liver disease in such patients.